Dr. Sara E. Maloney Norcross is a Principal Research Chemist in the Technology Advancement and Commercialization Division of RTI International, where she directs the program on inhaled drug delivery. She earned her Ph.D. in analytical chemistry from the University of North Carolina at Chapel Hill in Chapel Hill, NC, where she focused on developing nitric oxide-releasing biopolymers for various biomedical applications, including wound healing, catheter-related bloodstream infections, and cystic fibrosis-related infections. Her current research interests include the formulation and delivery of inhaled and intranasal therapeutics and vaccines for the treatment and prevention of pulmonary infections. She is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society of Aerosols in Medicine (ISAM), and the European Respiratory Society (ERS). Within AAPS, she serves as a leader of the Inhalation and Nasal Community.
Dr. Sara E. Maloney Norcross is a Principal Research Chemist in the Technology Advancement and Commercialization Division of RTI International, where she directs the program on inhaled drug delivery. She earned her Ph.D. in analytical chemistry from the University of North Carolina at Chapel Hill in Chapel Hill, NC, where she focused on developing nitric oxide-releasing biopolymers for various biomedical applications, including wound healing, catheter-related bloodstream infections, and cystic fibrosis-related infections. Her current research interests include the formulation and delivery of inhaled and intranasal therapeutics and vaccines for the treatment and prevention of pulmonary infections. She is a member of the American Association of Pharmaceutical Scientists (AAPS), the International Society of Aerosols in Medicine (ISAM), and the European Respiratory Society (ERS). Within AAPS, she serves as a leader of the Inhalation and Nasal Community.